CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Satish Reddy

Chairman, Dr. Reddy's Laboratories Ltd.

Search every verified Satish Reddy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In interviews conducted for the India Pharma Archives Oral History Project, Satish Reddy discussed Dr. Reddy's Laboratories' early entry into the Russian market and the company's drug discovery efforts. He recounted that the company's initial move into Russia was driven by founder Dr. Reddy's entrepreneurial instincts following a conference in Moscow after the Soviet breakup, leading to product registrations and the shipment of large quantities of medicines. Reddy described the market's subsequent volatility, including a ruble depreciation that forced the company to write off outstanding amounts and report no profit for one year, as well as a period when many competitors left. He stated that the company chose to remain in Russia despite advice to exit, citing the strength of its brands and a focus on providing affordable medicines, and that it later established a direct presence in the market. Regarding research and development, Reddy said that Dr. Reddy's Research Foundation was established in the early 1990s based on the conviction that the company's chemistry expertise could enable original drug discovery. He noted that compounds were licensed to Novo Nordisk, but that the program faced setbacks when animal studies revealed tumors and the PPAR class of compounds came under scrutiny, leading to the program's shutdown. He explained that the company subsequently reorganized its efforts, founding a wholly owned subsidiary called Axygen in 2002 to provide services and later shifting focus to oncology. Reddy stated that the company currently has several products in clinical trials, including phase two and phase three studies, and collaborations with biotech companies, while acknowledging that the goal of launching a drug developed from Dr. Reddy's stable globally remains unfinished.

Recent appearances

Notable quotes

“the next phase of the industry is really that how do we also move towards the highest value ad which is Discovery part of it and along the way there's also I mean again lot of terminology but even biologics for example because all that I talked about our initial success was chemistry based that's what we were strong in but then if you see most of the products today especially in the pipeline lot of these are biologic”

“1970 was the defining part but 2005 when the Indian patents Act was amended as part of the trips agreement right so which was again happened early '90s as part of the liberalization it was very clear to us that 2005 product patents would be recognized it was very clear in 1995 so what does Dr RI do in the year 1992 this is again unprecedented and I'll also talk about what Economist defined that as that event 1992 he ”

Other executives at Dr. Reddy's Laboratories Ltd.

  • G Prasad, Co-Chairman and Managing Director

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →